glp-1 drugs uses Medications: Everything You Need to Know The GLP-1 Agonists and Obesity:
Description
Percent change in weight from baseline to week 72 Primary outcome: Results Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72
A new paradigm for treating to target with second-generation obesity medications
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed for the management of type 2 diabetes, due to their role in enhancing insulin secretion, decreasing glucagon secretion, and delaying gastric emptying
Diabetes: new mechanism for insulin resistance
FDA has issued a box warning of the risk of thyroid cancers and are contraindicated liraglutide, exenatide (once weekly), and semaglutide (both oral and injectable) in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia types 2 A or 2B [135, 136]
Starting with small, simple meals and gradually advancing the diet can help minimize symptoms
